OrbiMed News
13 articles
growth-positive
OrbiMed Raises $4.3 Billion Across Private Investment Funds
Global healthcare investment firm OrbiMed has raised over $4.3 billion for its latest private investment funds, including OrbiMed Private Investments IX, OrbiMed Asia Partners V and OrbiMed Royalty & Credit Opportunities IV. These funds will allow OrbiMed to invest globally, from seed stage start-ups to growth capital opportunities. The firm works closely with its portfolio companies to provide tailored financing solutions. Investors in these new funds include a range of medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices.
Investment
OrbiMed Raises $3.5 Billion Across Private Investment Funds
growth-negative
OrbiMed chooses against raising a third Israeli healthcare-dedicated fund
Healthcare-dedicated investment firm OrbiMed will not be raising another fund in Israel, impacting the local ecosystem. The companys global leadership decided against setting up a third fund, but its Israeli partners will continue to work on follow-up investments in Israeli companies. OrbiMeds second fund, raised in 2016, amounted to $307 million. The company has invested in numerous Israeli companies and has recorded six exits. While OrbiMed will still invest in new Israeli companies through its global funds, its overall investment in the Israeli ecosystem is expected to decrease significantly.
Investment
growth-positive
OrbiMed floats fourth Asia healthcare PE fund VCCircle
Healthcare-focused investment firm OrbiMed has launched its fourth Asia private equity fund, aiming to raise $750 million. OrbiMeds previous Asia funds invested across the healthcare industry in the region, with a focus on growth-stage companies in China and India. The firm has previously invested in companies such as Advanced Enzyme Technologies, Entero Healthcare Solutions, and Vivimed Labs. Other healthcare-focused PE firms in India include Quadria Capital, InvAscent, Asian Healthcare Fund, and Somerset Health Capital Advisors.
Investment
OrbiMed Announces New General Partner
growth-positive
https://www.jpost.com/jpost-tech/business-and-innovation/israeli-digital-health-innovation-a-compelling-opportunity-for-investors-589397
Digital health start-ups in Israel have raised a record $511m in financing in 2018 and $214m in the first quarter of 2019. OrbiMed Advisors, a healthcare-dedicated investment firm, sees Israels digital health innovation sector as a compelling opportunity for international investors. Israel has a strong tech industry and is recognized as the number two hub for technology after Silicon Valley. The founders of digital health companies in Israel bring a different way of thinking and complementary networks, making them attractive to tech giants who may acquire them. Israels digital health start-up ecosystem has expanded rapidly, with 537 companies operating in the field. The government has approved a five-year national digital health plan to encourage technological development and regulatory changes. OrbiMed closed its second Israel-focused venture capital fund in 2016 with approximately $307m in commitments.
Investment
OrbiMed Seeks $1.2 Billion for Third Health-Care Royalty and Debt Fund
growth-positive
Orbimed Advisors Llc Buys Tricida Inc, Anthem Inc, Allergan PLC, Sells Regeneron Pharmaceuticals Inc, ARMO BioSciences Inc, AbbVie Inc
Orbimed Advisors Llc, a New York-based investment company, has made several purchases and sales in its portfolio during the three months ended 30 June 2018. The company initiated holdings in Tricida Inc, Anthem Inc, Inspire Medical Systems Inc, Tandem Diabetes Care Inc, Exelixis Inc, and UnitedHealth Group Inc. It also added to its holdings in Allergan PLC, Dentsply Sirona Inc, Ascendis Pharma A/S, Mylan NV, and Thermo Fisher Scientific Inc. Meanwhile, it sold out its holdings in ARMO BioSciences Inc, AbbVie Inc, Envision Healthcare Corp, Xencor Inc, Seres Therapeutics Inc, and Novelion Therapeutics Inc.
Investment
Neutral
OrbiMed Announces Completion of Leadership Transition
Samuel D. Isaly has transferred his controlling interest in OrbiMed and stepped down from his position as Managing Member of the firm. The terms of the transfer were not disclosed. The firm’s five other Partners, Sven H. Borho, Carl L. Gordon, Jonathan T. Silverstein, W. Carter Neild and Geoffrey C. Hsu, will continue their ownership of the firm. The Managing Member role has been transferred to Mr. Borho, Mr. Gordon and Mr. Silverstein.
Management Changes
growth-positive
OrbiMed launches $307m second Israel fund
OrbiMed has closed its second Israel-focused venture capital fund, OrbiMed Israel Partners II, with approximately $307 million in capital commitments. The fund will target all stages and sectors of the healthcare industry in Israel, with a focus on biopharmaceuticals, digital health, medical devices, and diagnostics companies. OrbiMeds strong track record in investing in Israel positions them as a significant partner to entrepreneurs and research institutions in the country.
Investment
growth-positive
OrbiMed to Raise $300M Healthcare Venture Capital Fund Focused on Israel - FinSMEs
OrbiMed Advisors is raising a $300m healthcare venture capital fund focused on Israel. No funds have been raised to date.
Investment
N/A
Buzz: OrbiMed mulls $250M Israeli investment fund
The article discusses the terms of use and privacy policy of Questex LLC.
growth-positive
OrbiMed's Israel Fund Invests $14 Million In Keystone Heart Ltd.
Keystone Heart Ltd., a developer of the TriGuard cerebral protection medical device, has raised $14 million in a Series B funding round led by OrbiMed. The funds will be used for a multi-center, randomized clinical trial in Europe and for a US Food and Drug Administration study. The TriGuard device is designed to minimize the risks of cerebral damage during heart surgeries. Keystone Heart aims to become a world leader in medical technologies. OrbiMed, a private equity and venture capital firm, specializes in healthcare investments.
Investment
